The Rifaximin Study in CVID
NCT01946906
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Common Variable Immunodeficiency (CVID)
Interventions
DRUG:
Rifaximin
Sponsor
Oslo University Hospital